Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.